Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stockBalaji Amines Ltd (BALAMINES) is currently trading at 1,040.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Balaji Amines Limited is an Indian specialty chemical manufacturer producing aliphatic amines, amine derivatives and specialty solvents primarily used by pharmaceuticals, agrochemicals and industrial customers; it operates multiple manufacturing units around Solapur and Medak, exports to 50+ countries and also owns the Balaji Sarovar Premiere five‑star hotel in Solapur. The company reported consolidated Q3FY26 revenue of approximately ₹336 crore with EBITDA of ₹61.7 crore and EBITDA margin around 18.3%; standalone operations are zero‑debt, margins remain resilient near 18–19%, but consolidated PAT and ROCE have moderated year‑to‑date owing to depreciation and ongoing capex. Balaji is pursuing targeted, high‑impact projects: a 100,000 TPA Dimethyl Ether (DME) plant, a 15,000 TPA electronic‑grade DMC facility commissioned for battery chemicals, a 5,000 TPA N‑Methyl Morpholine plant and a Rs.750 crore phased subsidiary expansion to manufacture HCN, NaCN, EDTA and EDA‑based derivatives, with many units aimed for FY2026–27 commissioning. Market positioning is strong: Balaji claims to be India’s largest aliphatic amines and methylamines manufacturer, operates forward integration into derivatives and specialty chemicals, holds REACH and WHO‑GMP certifications and maintains long‑term relationships with blue‑chip pharma customers, supporting export access and pricing resilience. Non‑core diversification exists but is small: the Balaji Sarovar Premiere hotel contributes under 3% of revenue yet reports high occupancy (~82%) and strong RevPAR, delivering incremental cash flow while the chemical business remains the primary earnings driver and focus of management.
Over the past 52 weeks, Balaji Amines Ltd has traded between a low of ₹905.15 and a high of ₹1,946.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Balaji Amines Ltd has a market capitalization of approximately 3,385.26. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Balaji Amines Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 23.50 and operates in the Chemicals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 3,385.26 Cr, Balaji Amines Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Balaji Amines Ltd operates in the Chemicals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Balaji Amines Ltd is 23.50. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
5
Neutral
4
Bullish
5
Bearish
37
Neutral
4
Bullish
5
Bearish
32
Neutral
0
Bullish
0
Newspaper Advertisement
Balaji Amines published a SEBI-linked newspaper notice that a Special Window for transfer and dematerialisation of physical shares is open from Feb 05, 2026 to Feb 04, 2027; transferred shares will be credited only in demat form and be locked‑in for one year; RTA contact details provided.
Newspaper Advertisement
Balaji Amines published a SEBI-regulation notice opening a special one-year window (05 Feb 2026–04 Feb 2027) to facilitate transfer and mandatory dematerialisation of physical shares; transferred shares to be credited in demat and locked for one year.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
866.00 | 3,736 Cr | 11.06 | 1.78 | 0.69 | 19.15 | 19.53 | 10.44 | |
1330.00 | 3,509 Cr | 177.81 | 4.39 | 0.08 | 4.11 | 5.72 | 0.86 | |
219.80 | 3,480 Cr | -12.16 | 118.39 | 0.00 | -11.18 | -1.13 | -4.46 | |
1040.00 | 3,385 Cr | 23.50 | 1.80 | 1.05 | 7.75 | 10.38 | 6.21 | |
452.50 | 3,323 Cr | -386.75 | 0.60 | 3.49 | 0.00 | 0.84 | -0.10 | |
491.45 | 3,298 Cr | 23.96 | 3.30 | 0.06 | 13.84 | 15.78 | 7.54 | |
62.96 | 2,855 Cr | 20.38 | 2.86 | 0.79 | 15.14 | 20.01 | 10.56 |
Balaji Amines Limited is an Indian specialty chemical manufacturer producing aliphatic amines, amine derivatives and specialty solvents primarily used by pharmaceuticals, agrochemicals and industrial customers; it operates multiple manufacturing units around Solapur and Medak, exports to 50+ countries and also owns the Balaji Sarovar Premiere five‑star hotel in Solapur.
The company reported consolidated Q3FY26 revenue of approximately ₹336 crore with EBITDA of ₹61.7 crore and EBITDA margin around 18.3%; standalone operations are zero‑debt, margins remain resilient near 18–19%, but consolidated PAT and ROCE have moderated year‑to‑date owing to depreciation and ongoing capex.
Balaji is pursuing targeted, high‑impact projects: a 100,000 TPA Dimethyl Ether (DME) plant, a 15,000 TPA electronic‑grade DMC facility commissioned for battery chemicals, a 5,000 TPA N‑Methyl Morpholine plant and a Rs.750 crore phased subsidiary expansion to manufacture HCN, NaCN, EDTA and EDA‑based derivatives, with many units aimed for FY2026–27 commissioning.
Market positioning is strong: Balaji claims to be India’s largest aliphatic amines and methylamines manufacturer, operates forward integration into derivatives and specialty chemicals, holds REACH and WHO‑GMP certifications and maintains long‑term relationships with blue‑chip pharma customers, supporting export access and pricing resilience.
Non‑core diversification exists but is small: the Balaji Sarovar Premiere hotel contributes under 3% of revenue yet reports high occupancy (~82%) and strong RevPAR, delivering incremental cash flow while the chemical business remains the primary earnings driver and focus of management.
Chemicals
Chemicals - Speciality - Large
3,385 Cr
High Risk
23.5
42.9
1.0
1.8
1,946.00
905.15
Sales CAGR
Profit CAGR
ROE
ROCE
